New study aims to find best myeloma treatment for seniors
NCT ID NCT03829371
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at which treatment works best for older adults (65+) with multiple myeloma who cannot have a stem cell transplant. It compares standard drug combinations with or without daratumumab, a targeted antibody. The goal is to find the best balance of benefits, side effects, and quality of life for this group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dipartimento di Biotecnologie Molecolari e Scienze per la Salute
Torino, TO, 10126, Italy